Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Receives Average Recommendation of “Moderate Buy” from Analysts

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) has been assigned an average recommendation of “Moderate Buy” from the twenty-seven brokerages that are currently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, three have issued a hold recommendation and twenty-three have issued a buy recommendation on the company. The average 12-month target price among brokers that have covered the stock in the last year is $482.1688.

ALNY has been the topic of several research analyst reports. Canaccord Genuity Group upped their price objective on Alnylam Pharmaceuticals from $390.00 to $415.00 and gave the company a “buy” rating in a research report on Friday, August 1st. Wells Fargo & Company upped their price target on shares of Alnylam Pharmaceuticals from $395.00 to $479.00 and gave the stock an “equal weight” rating in a report on Tuesday, November 11th. Jefferies Financial Group reduced their price target on shares of Alnylam Pharmaceuticals from $550.00 to $549.00 and set a “buy” rating on the stock in a research note on Thursday, October 30th. Citigroup boosted their price objective on shares of Alnylam Pharmaceuticals from $527.00 to $583.00 and gave the company a “buy” rating in a research report on Tuesday, September 2nd. Finally, The Goldman Sachs Group upped their target price on shares of Alnylam Pharmaceuticals from $504.00 to $566.00 and gave the stock a “buy” rating in a research note on Tuesday, September 16th.

Insider Activity at Alnylam Pharmaceuticals

In other news, EVP Kevin Joseph Fitzgerald sold 12,128 shares of the firm’s stock in a transaction on Monday, November 17th. The stock was sold at an average price of $452.18, for a total transaction of $5,484,039.04. Following the transaction, the executive vice president owned 21,264 shares in the company, valued at approximately $9,615,155.52. This trade represents a 36.32% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Jeffrey V. Poulton sold 3,821 shares of the company’s stock in a transaction dated Thursday, October 2nd. The stock was sold at an average price of $452.05, for a total transaction of $1,727,283.05. Following the completion of the sale, the executive vice president directly owned 54,052 shares of the company’s stock, valued at approximately $24,434,206.60. This trade represents a 6.60% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 78,328 shares of company stock worth $35,705,793 over the last three months. Corporate insiders own 1.50% of the company’s stock.

Institutional Investors Weigh In On Alnylam Pharmaceuticals

Several hedge funds have recently modified their holdings of ALNY. Brighton Jones LLC bought a new position in Alnylam Pharmaceuticals in the fourth quarter worth approximately $243,000. Mutual of America Capital Management LLC increased its holdings in shares of Alnylam Pharmaceuticals by 673.9% in the 1st quarter. Mutual of America Capital Management LLC now owns 13,644 shares of the biopharmaceutical company’s stock valued at $3,684,000 after acquiring an additional 11,881 shares during the period. Cetera Investment Advisers raised its position in shares of Alnylam Pharmaceuticals by 68.1% in the 1st quarter. Cetera Investment Advisers now owns 8,017 shares of the biopharmaceutical company’s stock worth $2,165,000 after acquiring an additional 3,247 shares in the last quarter. Assetmark Inc. lifted its stake in shares of Alnylam Pharmaceuticals by 6.1% during the 1st quarter. Assetmark Inc. now owns 10,641 shares of the biopharmaceutical company’s stock worth $2,873,000 after purchasing an additional 608 shares during the last quarter. Finally, HB Wealth Management LLC bought a new stake in Alnylam Pharmaceuticals during the first quarter valued at about $208,000. Hedge funds and other institutional investors own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Trading Down 1.0%

ALNY opened at $429.80 on Wednesday. The company has a debt-to-equity ratio of 4.10, a quick ratio of 2.75 and a current ratio of 2.80. The stock’s 50 day moving average price is $456.13 and its 200-day moving average price is $393.87. Alnylam Pharmaceuticals has a one year low of $205.87 and a one year high of $495.55. The stock has a market cap of $56.78 billion, a price-to-earnings ratio of -174.01 and a beta of 0.30.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.